These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8607528)

  • 1. Should we treat cholestatic liver disease with cholesterol synthesis inhibitors?
    Schmidt HH; Manns MP
    Am J Gastroenterol; 1996 Feb; 91(2):406-7. PubMed ID: 8607528
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
    Olsson R
    Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA; Sanyal AJ
    Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.
    Ghonem NS; Boyer JL
    Hepatology; 2013 May; 57(5):1691-3. PubMed ID: 23174993
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of cholestatic liver diseases].
    Karvonen AL
    Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
    [No Abstract]   [Full Text] [Related]  

  • 8. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
    Serfaty L; Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
    [No Abstract]   [Full Text] [Related]  

  • 11. FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
    Alawad AS; Levy C
    Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of primary biliary cirrhosis].
    Szalay F
    Orv Hetil; 2003 Sep; 144(36):1787-8. PubMed ID: 14579676
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of cholestatic liver disease and therapeutic approaches.
    Hirschfield GM; Heathcote EJ; Gershwin ME
    Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
    Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

  • 16.  The effect of ursodeoxycholic acid in cystic cholangiopathies.
    Lammert F; Méndez-Sánchez N
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):949-950. PubMed ID: 27740534
    [No Abstract]   [Full Text] [Related]  

  • 17. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the therapy of cholestatic liver disease.
    Roda E; Parini P; Bazzoli F; Mazzella G; Festi D; Aldini R
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():53-5. PubMed ID: 1577396
    [No Abstract]   [Full Text] [Related]  

  • 20. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.
    Levy C; Angulo P
    Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.